Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective

Table 3 Costs, QALYs and ICER values for all analyzed populations

Incremental	SC								IV	Oral
Incremental	SEC	ETN	ETN BS	ADA	ADA BS	CER P	GOL	UST	INF	APR
SEC 150 mg versus comparators in Biologic Naïve population without moderate to severe psoriasis)
Total cost (€)	187,776	208,375	186,581	207,568	186,543	204,899	197,566	214,749	230,650	192,319
QALYs	8.01	7.67	7.67	7.47	7.47	7.34	7.15	7.54	8.07	7.13
ICER (€/QALY)	–	Dominates	3514	Dominates	2283	Dominates	Dominates	Dominates	680,427^a	Dominates
SEC 300 mg versus comparators in Naïve PsA with moderate to severe psoriasis population
Total cost (€)	231,477	214,225	192,431	213,555	192,530	210,480	203,855	220,313	235,354	198,422
QALYs	7.78	7.12	7.12	6.9	6.9	6.78	6.57	6.98	7.54	6.57
ICER (€/QALY)	–	25,872	49,365	20,342	37,251	20,955	22,819	13,941	Dominates	27,233
SEC 300 mg versus comparators in experienced population
Total cost (€)	256,019 €	215,772	194,424	210,940	191,975	211,230	201,556	217,194	231,440	196,293
QALYs	8.75	7.35	7.35	7.05	7.05	7.00	6.75	7.12	7.61	6.68
ICER (€/QALY)	–	28,742	40,546	26,609	34,959	25,623	27,293	23,832	21,631	28,939

ADA, adalimumab; APR, apremilast; BS, biosimilar; CER P, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; IV, Intra Venous; PsARC, Psoriatic arthritis response criteria; QALY, quality-adjusted life-year; SEC 150, secukinumab 150 mg; SEC 300, secukinumab 300 mg; SC, subcutaneous; SoC, standard of care; UST, ustekinumab
^aThe ICER of Sec 150 mg vs. INF

ISSN: 1478-7547